FREQUENCY ANALYSIS OF MEDICINAL PRESCRIPTS AT PHARMACOTHERAPY OF BRONCHIAL ASTHMA IN CHILDREN

Iryna Kostiuk, Olha Dziuba, Mikola Makukha, Larisa Golopikho

Abstract


Today, bronchial asthma is the most widespread childhood chronic respiratory disease in the world. To make managerial decisions in the health care system of Ukraine and to identify priority areas for the response to this disease, it is necessary to carry out a quantitative analysis of the appointment letters and the proportion of patients who received specific drugs for determining the main areas of therapy.

Aim. Carrying out of frequency analysis of medical prescriptions at pharmacotherapy of bronchial asthma in children.

Materials and methods. 574 medical cards of an indoor patient with the main diagnosis of "Bronchial asthma", received at the Kyiv City Children's Clinical Hospital №2. A retrospective frequency analysis of the prescribing of drugs for archival data of appointment letters was conducted.

Results. The conducted analysis of patients by age and sex allowed to establish the correspondence of the obtained results with the results of previous scientific studies on gender differences in the prevalence of bronchial asthma in children. In 45.3 % of the children, the length of stay was 2-10 days, and in 37.3 % – 11–20 days, indicating a sufficiently long period of inpatient treatment. According to the letters of appointment in the medical records of the inpatient patient, the physicians carried out 1983 appointments, of which 1867 were medicated (94.2 %), and 116 were non-medicated methods (5.8 %). The medical appointments of doctors included 1763 medicines. Of these, 94.4 % are medicines belonging to 11 groups according to ATC classification, 1.5 % – solutions for washing, irrigation, treatment, 0.3 % - dietary supplements, 0.1 % – homeopathic preparations, 3.7 % – other. The data that was obtained when calculating the intensity of the target varies in the range of 0.0006 to 0.07. The highest rates had only 2 drugs – Ventolin nebuli and Pulmicort, which were available in 22.3 % and 23.0 % of the patient's medical cards respectively, that is, every fifth patient. It was found that the ratio of drugs of domestic and foreign manufacture is 34.2 % (20 pharmaceutical companies) and 65.8 % (25 producing countries), respectively.

Conclusions. The received data of the conducted analysis of prescriptions of medicinal products allow establishing a significant nomenclature of medical appointments for children with bronchial asthma. The promising direction for domestic pharmaceutical companies in the production of drugs for the treatment of the examined nosology was revealed. At the same time, the frequency analysis of the nomenclature of drugs can be used in the selection of drugs for reimbursement programs and medical insurance after further pharmacoeconomic studies.


Keywords


bronchial asthma in children; pharmacotherapy; nomenclature of medicinal products; medicinal products

Full Text:

PDF

References


Kanavos, P., Schurer, W., Vogler, S. (2011). The Pharmaceutical Distribution Chain in the European Union: Structure and Impact on Pharmaceutical Prices. London: London School of Economics, 120.

Lenney, W., Bush, A., Fitzgerald, D. A., Fletcher, M., Ostrem, A., Pedersen, S. et. al. (2018). Improving the global diagnosis and management of asthma in children. Thorax, 73 (7), 662–669. doi: http://doi.org/10.1136/thoraxjnl-2018-211626

Ferreira de Magalhães, M., Amaral, R., Pereira, A. M., Sá-Sousa, A., Azevedo, I., Azevedo, L. F., Fonseca, J. A. (2017). Cost of asthma in children: A nationwide, population-based, cost-of-illness study. Pediatric Allergy and Immunology, 28 (7), 683–691. doi: http://doi.org/10.1111/pai.12772

Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry bronkhialnii astmi (2013). Nakaz MOZ Ukrainy vid 08.10.2013 No. 868. Available at: https://zakon.rada.gov.ua/rada/show/v0868282-13

Osnovy zakonodavstva Ukrainy pro okhoronu zdorovia (1992). Zakon Ukrainy vid 19.11.1992 No. 2801-XII. Available at: https://zakon.rada.gov.ua/laws/show/2801-12

Pro zatverdzhennia Kontseptsii rozvytku farmatsevtychnoho sektoru haluzi okhorony zdorovia Ukrainy na 2011–2020 roky (2010). Nakaz MOZ Ukrainy vid 13.09.2010. No. 769. Available at: https://zakon.rada.gov.ua/rada/show/v0769282-10

Piniazhko, O. B. (2016). Analiz realnykh danykh pryznachen likarskykh zasobiv pry poshyrenykh hinekolohichnykh zakhvoriuvan v Ukraini. Farmatsevtychnyi zhurnal, 3-4, 29–41.

Mishchenko, O. Ya., Yakovlieva, L. V., Ostashko, V. F. (2016). Rezultaty chastotnoho analizu pryznachen likarskykh zasobiv khvorym na ishemichnu khvorobu sertsia yak kryterii otsinky yakosti farmakoterapii. Klinichna farmatsiia, 4, 24–28.

Yakovlieva, L. V., Mishchenko, O. Ya. (2016). Kliniko-ekonomichnyi analiz farmakoterapii khvorykh na liushboishialhiiu. Ratsionalna farmakoterapiia, 2, 19–24.

Zaiats, M. M., Zimenkovskyi, A. B. (2013). Kliniko-ekonomichnyi analiz yak skladova optymizatsii farmakoterapii metabolichnoho syndromu. Zaporizkyi medychnyi zhurnal, 4, 10–12.

Masheiko, A. M., Makarenko, O. V., Mavrutenkov, V. V. (2016). Kliniko-ekonomichnyi analiz vytrat na farmakoterapiiu hostroho tonzylitu v umovakh statsionaru. Farmatsevtychnyi chasopys, 41, 48–53. doi: http://doi.org/10.11603/2312-0967.2016.4.7121

Tkachova, O. V., Silaiev, A. O. (2016). Kliniko-ekonomichnyi analiz farmakoterapii khvorykh na khronichnyi kholetsystyt. Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 1, 80–85.

Nemchenko, A. S., Balynska, M. V. (2016). Rezultaty kliniko-ekonomichnoho analizu spozhyvannia likarskykh preparativ khvorym dytiachoho viku na virusnu diareiu. Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 3, 60–67.

Tkachova, O. V., Silaiev, A. O. (2016). Kliniko-ekonomichnyi analiz farmakoterapii ditei z hostrym nazofarynhitom. Sotsialna farmatsiia v okhoroni zdorovia, 3, 75–82.

Fediak, I. O. (2014). Rezultaty kliniko-ekonomichnoho analizu farmatsevtychnoho zabezpechennia ditei z kashliukom, skarlatynoiu, meninhokokovoiu infektsiieiu. Klinichna farmatsiia, 18 (1), 29–34.

Bieliaieva, O. I. (2012). Kliniko-ekonomichni kharakterystyky farmakoterapii poza likarnianoi pnevmonii u ditei. Farmatsevtychnyi chasopys, 4, 163–168.

Gerasymova, O. O., Meshcheryakova, I. V. (2017). Clinical and economic analysis of the pharmacotherapy in children with functional dyspepsia. Clinical pharmacy, 21 (1), 19–24. doi: http://doi.org/10.24959/cphj.17.1415

Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry bronkhialnii astmi (2013). Nakaz MOZ Ukrainy vid 08.10.2013. No. 868. Available at: https://zakon.rada.gov.ua/rada/show/v0868282-13

Bilak, V. M., Chonka, Ya. V., Bilak, I. D. (2013). Stan reaktyvnosti bronkhiv u ditei, khvorykh na bronkhialnu astmu, pid vplyvom likuvannia metodom speleoterapii. Problemy klinichnoi pediatrii, 3, 14–17.

Maidannyk, V. H., Smiian, O. I. (2017). Bronkhialna astma u ditei. Sumy: Sumskyi derzhavnyi universytet, 243.




DOI: http://dx.doi.org/10.21303/2504-5679.2019.00916

Refbacks

  • There are currently no refbacks.




Copyright (c) 2019 Iryna Kostiuk, Olha Dziuba, Mikola Makukha, Larisa Golopikho

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2504-5679 (Online), ISSN 2504-5660 (Print)